This study will describe the prescription conditions of botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) or idiopathic overactive bladder (IOAB) as per standard of care in clinical practice in France.
Study Type
OBSERVATIONAL
Enrollment
474
Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.
Target Patients Prescribed Botox® in Clinical Practice
Time frame: Day 1
Treatments Previously Prescribed
Time frame: Day 1
Number of Sites Injected
Time frame: Day 1
Total Dose of Botox® Used
Time frame: Day 1
Types of Anaesthesia and Antibiotic Prophylaxis Used
Time frame: Day 1
Cytobacteriological Examination of the Urine
Time frame: Day 1
Total Number of Botox® Cycles in Non-naive Patients (previously received Botox®)
Time frame: Day 1
Length of Botox® Treatment in Non-naive Patients
Time frame: Day 1
Time Since Last Botox® Injection in Non-naive Patients
Time frame: Day 1
Characteristics of Injector Sites (Locations)
Time frame: Day 1
Characteristics of Injector Physicians
Time frame: Day 1
Characteristics of Patients
Time frame: Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Site D'Aix En Provence
Aix-en-Provence, France
CL Toulouse Lautrec
Albi, France
CHU Angers
Angers, France
CH Angouleme
Angoulême, France
CH Avranches Granville
Avranches, France
CH Bagnols Sur Ceze
Bagnols-sur-Cèze, France
CH Belfort
Belfort, France
CHU Besancon
Besançon, France
CL Saint Augustin
Bordeaux, France
CHU Bordeaux
Bordeaux, France
...and 40 more locations
Number of Patients by Pathology History
Time frame: Day 1
Number of Patients by Medical and Surgical History
Time frame: Day 1
Reduction of Number of Daily Urinary Incontinence Episodes in Non-naive Patients
Time frame: Day 1
Percentage of Continent Patients in Non-naive Patients
Time frame: Day 1
Number of Adverse Events during the Visit
Time frame: Day 1